A narrative review in Clinics in Dermatology argues that dermatologists should use shared decision-making to guide GLP-1 receptor agonist use, balancing dermatologic side effects such as facial volume loss, hair shedding, and gastrointestinal intolerance against patient selection. The review notes…
A narrative review in Clinics in Dermatology argues that dermatologists should use shared decision-making to guide GLP-1 receptor agonist use and related incretin therapies, balancing dermatologic side effects against patient selection. The review repositions a drug class that most clinicians still file under endocrinology and cardiometabolic care as a working concern for dermatology. GLP-1 receptor agonists and related incretin therapies have moved rapidly from second-line diabetes agents to widely prescribed cardiometabolic medications, and the review argues the specialty now needs a deliberate approach to them.
Dermatologists increasingly encounter patients already taking these therapies, whether or not the dermatologist wrote the prescription. The review defines two clinical tasks from that encounter. The first is managing cutaneous consequences in current users. The second is deciding when to raise the possibility of therapy in eligible patients who may benefit. Neither task fits comfortably inside a standard dermatology residency, which is precisely why the review treats them as a new area of clinical competence rather than a footnote to metabolic care.
The gap on that second task is large. Most eligible patients are not receiving GLP-1 receptor agonist therapy, and nearly all current prescriptions originate outside dermatology. Obesity is common among dermatology patients and is particularly prevalent in psoriasis and hidradenitis suppurativa , so the patients who populate inflammatory dermatology clinics overlap heavily with the patients for whom cardiometabolic therapy is medically indicated. That overlap is the clinical basis for the review's argument: dermatologists are part of the prescribing conversation whether they choose to be or not.
The review's insistence on shared decision-making follows from the nature of the tradeoffs. Evidence in this area is still evolving, treatment can reshape how patients look and feel, and the patients involved often carry a chronic inflammatory skin disease on top of a cardiometabolic condition. A fixed protocol would not fit that combination. The review argues that a framework for joint decisions, in which the clinician lays out what is known and the patient weighs what matters, is the appropriate response to the uncertainty.
The venue is part of the argument. A journal devoted to clinical dermatology is not the obvious home for a prescribing framework for a metabolic drug class, and the review's placement there is a statement that this is a dermatology concern rather than a referral courtesy. The review casts the dermatologist as a participant in the metabolic treatment plan: someone who manages consequences, monitors skin outcomes, and, in the right patient, opens a conversation that may end in a prescription written elsewhere. That is a change in professional role, and the review is explicit about its origin. The prescriptions are coming from other clinics. Dermatologists are seeing the results.
The article is organized around five questions, each of them chosen for the dermatology visit rather than the metabolic clinic:
The population in view is the dermatology patient. That includes people with psoriasis and hidradenitis suppurativa who are already taking or may be eligible for GLP-1 receptor agonist therapy. Obesity is common among dermatology patients and is particularly prevalent in both diseases, which is why the review treats the dermatology clinic as a plausible site for initiating discussion rather than a place where the therapy only shows up as a problem.
The selection question is the most forward-looking. A metabolic and inflammatory phenotype, in this context, means a patient whose skin disease is entangled with measurable metabolic disease: elevated body mass index, impaired glucose tolerance, or an inflammatory picture whose severity tracks with weight. Psoriasis and hidradenitis suppurativa both fit that description in a substantial subset of patients. The review does not claim that incretin therapy has been proven to improve either disease. It argues that patients with that combination are the plausible candidates for dermatologic benefit, and that identifying them requires a structured conversation rather than a glance at the chart.
The practical demands of therapy are the part of the discussion that determines whether treatment succeeds in daily life. GLP-1 receptor agonists are injectable, they require dose titration, and their early gastrointestinal effects push many patients to stop in the first weeks or months. Persistence matters because the metabolic gains largely reverse when the drug is discontinued. Cost, insurance coverage, and access to the drug vary widely, and a patient who starts without understanding those demands is a patient likely to stop early and attribute the failure to the drug itself. The review's endpoint treats these demands as central to the prescribing decision, not as logistics to be worked out later.
Grouping the three adverse effects together reframes them. Facial volume loss and hair shedding rarely appear in metabolic trial adverse-event summaries, but they are exactly the effects that patients see in the mirror and that shape whether therapy feels worth continuing. Gastrointestinal intolerance is the class's best-known tolerability limit. The review's contribution is to treat all three as a single dermatologic management problem and to give clinicians a structure for addressing them, rather than leaving each one to be discovered in passing.
The monitoring question gives the framework its clinical anchor. The dermatology visit has something the metabolic clinic often lacks: a visible, measurable target. Skin disease activity can be scored, photographed, and tracked over time, which makes the dermatology clinic a natural place to observe whether a metabolic intervention is changing the inflammatory picture while the therapy's adverse effects are also being managed. The monitoring approach the review calls for is one that fits inside a routine dermatology visit rather than requiring a separate specialty clinic.
The five questions are sequential in practice. Selection determines which patients are offered therapy. The practical demands determine whether an offer converts into sustained use. The adverse effects determine whether sustained use is tolerable. Monitoring ties the sequence to measurable skin outcomes, and shared decision-making is the process that connects each step to the patient's own priorities. Skip any one of the questions and the result is a prescription that is metabolically appropriate but behaviorally fragile.
The article is a narrative review, not a systematic review and not an original clinical study. A narrative review selects and interprets literature according to the authors' judgment rather than a prespecified search and analytic protocol. That design gives the authors room to connect separate literatures, which matters here because the relevant evidence spans metabolic medicine, gastroenterology, and dermatology. The cost of that freedom is evidentiary precision: a narrative review cannot generate new data, cannot measure the prevalence of the adverse effects it discusses, and cannot establish that incretin therapy causes dermatologic changes rather than merely accompanying them.
The distinction between a narrative review and a systematic review is not cosmetic. A systematic review begins with a registered protocol, an exhaustive search strategy, predefined inclusion criteria, and a structured assessment of study quality, so its conclusions can be audited and reproduced. A narrative review is an argument built from selected evidence, and its value depends on the authors' command of the field and the transparency of their reasoning. Both forms can be wrong, but they are wrong in different ways. A systematic review can be criticized for its protocol; a narrative review can be criticized for its selection of sources.
The endpoints the review addresses are clinical and practical rather than statistical. There is no sample size, no comparator arm, and no duration, because there is no enrolled patient population. What the design supports is a management argument: the review identifies facial volume loss, hair shedding, and gastrointestinal intolerance as the dermatology-relevant adverse effects patients most often notice, and it argues that shared decision-making offers a useful framework while the evidence base continues to evolve. Those are interpretive conclusions drawn from the literature, and they are meant to guide practice and research, not to close either.
The review flags its own limits directly. Evidence in this area is still evolving, and the source is a narrative review rather than a controlled study. Within those limits the article functions as a clinical brief. It tells a dermatologist what to look for, what to ask about, and how to structure a conversation with a patient whose options involve real tradeoffs. It also functions as a research agenda, because every management question it raises is a study waiting to be designed.
A narrative review also demands a particular reading discipline. The reader should ask whether the authors separate mechanism-based expectation from clinical evidence, whether each claim is anchored to data the reader could inspect, and whether the management advice would survive the arrival of contrary results. The review largely meets that standard: it frames dermatologic benefit as plausible rather than proven, and it anchors its practical advice in the adverse effects it identifies as the ones patients most often notice. What it cannot supply is quantification, and it does not pretend to. Those numbers, if they exist at all, sit in individual clinics and unpublished case series, which is the gap the review's monitoring agenda is designed to close.
The pharmacology of the class explains why it arrived in the dermatology clinic. Glucagon-like peptide-1 is an incretin hormone released by intestinal L cells in response to nutrient intake. GLP-1 receptor agonists amplify glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and, through receptors in the central nervous system, contribute to satiety. The related incretin therapies extend this pharmacology by engaging additional incretin receptor targets beyond GLP-1, and the resulting weight loss and cardiometabolic effects are what carried the class from second-line diabetes status to broad prescribing.
One feature of the class matters specifically for the dermatology visit: the mechanism is glucose-dependent. GLP-1 receptor agonists potentiate insulin secretion only when blood glucose is elevated, which gives the class a comparatively low risk of hypoglycemia outside patients who also use insulin or sulfonylureas. That safety profile is one reason the drugs could move beyond specialist diabetes care into broad cardiometabolic prescribing. It also means the tolerability problem patients actually feel is not metabolic but gastrointestinal, which is consistent with the review's emphasis. The gap between the physiological risk profile and the experienced side-effect profile explains a puzzle a dermatologist will meet in practice: a patient can be metabolically stable and still stop the drug because of how the…
Peptides referenced: Glucagon, GLP-1.
Related reading: Stage-gated workflow proposed for meat-derived bioactive peptides, GLP-1 therapies cast as pain adjuncts, not primary analgesics, Microbiota safety should shape antimicrobial peptide development, Semaglutide Biomarker Gains Clash With Missed Alzheimer's Endpoints.